The stock opened at Rs 5202 and touched an intraday high and low of Rs 5213.5 and Rs 5070.45, respectively, in the session so far. The stock of Dr. Reddy’s Laboratories Ltd. quoted a 52-week high of Rs 5514.65 and a 52-week low of Rs 2497.6.
Total market cap of the Dr. Reddy’s Laboratories Ltd. stood at Rs 84630.23 crore at the time of writing this report.
The pharma major said it along with Russian Direct Investment Fund (RDIF) has received approval from the Drug Control General of India (DCGI) to conduct phase 2/3 human clinical trials for COVID-19 vaccine Sputnik V in India.
The company reported consolidated net sales of Rs 4417.5 crore for the quarter ended 30-Jun-2020, down 0.32 per cent from previous quarter’s Rs 4431.8 crore and down 14.93 per cent from the year-ago quarter’s Rs 3843.6 crore.
The net profit for latest quarter stood at Rs 594.6 crore, down 12.11 per cent from the corresponding quarter last year.
As of 30-Sep-2020, DIIs held 11.37 per cent stake in the company, while foreign institutional investors held 29.58 per cent and the promoters 26.74 per cent.
According to BSE data, the stock traded at a P/E multiple of 43.53 and a price-to-book ratio of 3.32. A higher P/E ratio shows investors are willing to pay a higher price because of better future growth expectations. Price-to-book value indicates the inherent value of a company and is the measure of the price that investors are ready to pay even for no growth in the business.
Dr. Reddy’s Laboratories Ltd. belongs to the Pharma – Indian industry.